Oncologists presenting at a medical conference in Barcelona unveiled clinical trial results showing an experimental pill combined with standard chemotherapy shrank or eliminated pancreatic tumors in most trial participants, marking what advocates called the most significant advance for the disease in decades.
The study evaluated the drug daraxonrasib alongside two chemotherapy medications in 61 patients with advanced pancreatic cancer that had spread to other organs. According to trial findings presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, tumors shrank or disappeared in more than 60 percent of participants, while disease progression was halted in 90 percent of patients.
Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York and the trial’s principal investigator, described the results as “the closest to cure” he had witnessed in patients with metastatic pancreatic cancer, Bioengineer.org reported.
Unprecedented Trial Results
During the trial, known as RMC-GI-102, patients received a daily 200-milligram dose of daraxonrasib together with intravenous chemotherapy drugs gemcitabine and nab-paclitaxel. Data collected through Sept. 28, 2026, with a median follow-up period of 18.3 months, showed that 8.2 percent of participants achieved a complete response, meaning their tumors became undetectable on diagnostic imaging scans.
The treatment produced a median progression-free survival of 12.8 months, roughly doubling the typical five to six months seen with traditional chemotherapy alone. Additionally, 76.6 percent of patients were alive one year after starting the combination therapy. Standard chemotherapy regimens historically yield one-year survival rates between 40 and 45 percent.
“We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival,” Park said during his presentation in Spain, as reported by The Guardian.
Targeting the ‘Death Star’ Gene
Pancreatic cancer is widely considered one of the deadliest forms of cancer, with a five-year survival rate of approximately 3 percent once the disease disseminates to other organs. More than nine in 10 pancreatic tumors carry a mutation in the RAS gene family—specifically KRAS—which acts as a cellular switch that remains locked on, driving rapid cell division and tumor growth.
Daraxonrasib is designed as a RAS inhibitor that directly targets and binds to the active protein configuration, blocking the biological signals that allow malignant cells to multiply. Because of its long-standing resistance to pharmaceutical interventions, researchers previously referred to the mutated protein as the “Death Star,” according to The Telegraph.
Michelle Mitchell, chief executive of Cancer Research UK, hailed the trial outcome as a landmark moment for oncology.
“This is the biggest leap forward we’ve seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers,” Mitchell said, according to The Guardian.She added that the drug could potentially open avenues for treating other cancers carrying similar genetic alterations, including colorectal, lung and gynecological malignancies.
Next Steps and Phase III Testing
Side effects observed during the trial were consistent with the expected impacts of the combined medications. The most common adverse events included skin rashes, diarrhea, fatigue and reduced blood cell counts, Bioengineer.org reported. Discontinuation of the trial drug due to side effects occurred in 5 percent of participants.
Despite the positive outcomes, researchers emphasized that the early-phase trial did not include a direct control group receiving chemotherapy alone. To confirm the findings, investigators have launched a global Phase III trial named RASolute-303. Led by Park, the larger randomized study will evaluate daraxonrasib both as a standalone therapy and in combination with chemotherapy against standard treatments.



